Clene (NASDAQ:CLNN – Get Free Report)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a report released on Monday, Benzinga reports.
Separately, Weiss Ratings raised shares of Clene from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, October 9th. Six research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Clene has an average rating of “Moderate Buy” and an average price target of $34.00.
Check Out Our Latest Research Report on CLNN
Clene Price Performance
Shares of CLNN traded up $0.22 during mid-day trading on Monday, hitting $3.32. 52,833 shares of the company’s stock were exchanged, compared to its average volume of 220,647. The company has a market cap of $43.13 million, a PE ratio of -0.95 and a beta of 0.91. Clene has a 52 week low of $3.02 and a 52 week high of $13.50. The company has a 50-day simple moving average of $4.04 and a 200 day simple moving average of $5.33.
Clene (NASDAQ:CLNN – Get Free Report) last issued its quarterly earnings results on Friday, August 14th. The company reported ($1.08) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.71). The firm had revenue of $0.09 million for the quarter, compared to the consensus estimate of $0.06 million. On average, analysts anticipate that Clene will post -1.70 earnings per share for the current year.
About Clene
Clene Inc (NASDAQ: CLNN) is a clinical-stage biopharmaceutical company developing nanotherapeutic medicines for neurodegenerative diseases. The company’s platform uses clean-surfaced nanocrystals designed to influence cellular energy production and support the health and function of nerve cells.
Clene’s lead product candidate is CNM-Au8, an orally administered suspension of gold nanocrystals. The company has studied CNM-Au8 in conditions including amyotrophic lateral sclerosis (ALS), multiple sclerosis and Parkinson’s disease, with research focused on potential neuroprotective and remyelinating effects.
Featured Stories
- Five stocks we like better than Clene
- Illinois Tool Works Faces Headwinds—2 Alternatives Stand Out
- Luxury’s Middle Market Is Cracking—These 3 Stocks Could Win
- Rate-Resilient vs. Rate-Exposed: Why Homebuilder Stocks Are Diverging
- The AI Trade Just Moved Into Your Bloodstream, and 4 Healthcare Stocks Are Winning
Receive News & Ratings for Clene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clene and related companies with MarketBeat.com's FREE daily email newsletter.
